|
US7244827B2
(en)
|
2000-04-12 |
2007-07-17 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
|
|
US6943235B1
(en)
*
|
1999-04-12 |
2005-09-13 |
Agensys, Inc. |
Transmembrane protein expressed in prostate cancer
|
|
US20050255106A1
(en)
*
|
1999-05-22 |
2005-11-17 |
Linda Diehl |
Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40
|
|
US20030059427A1
(en)
*
|
2000-04-28 |
2003-03-27 |
Force Walker R. |
Isolation and characterization of highly active anti-CD40 antibody
|
|
CA2422204A1
(en)
|
2000-09-07 |
2002-03-14 |
John R. Schreiber |
Human antibodies against pseudomonas aeruginosa lps derived from transgenic mice
|
|
EP2009027B1
(en)
|
2001-04-27 |
2014-05-21 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-CD40 monoclonal antibody
|
|
US7658924B2
(en)
*
|
2001-10-11 |
2010-02-09 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
JP2005519586A
(ja)
|
2001-11-21 |
2005-07-07 |
セルテック アール アンド ディー, インコーポレイテッド |
Cd83遺伝子産物を利用したサイトカイン・レベルの操作法
|
|
US20040185040A1
(en)
|
2001-11-21 |
2004-09-23 |
Celltech R & D Limited |
Modulating immune responses
|
|
PT1531850E
(pt)
*
|
2002-06-07 |
2012-05-07 |
Zymogenetics Inc |
Utilização de il-21 e anticorpo monoclonal para tratar cancros sólidos
|
|
US7052694B2
(en)
*
|
2002-07-16 |
2006-05-30 |
Mayo Foundation For Medical Education And Research |
Dendritic cell potentiation
|
|
HN2004000285A
(es)
*
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
|
CA2762955A1
(en)
*
|
2003-10-16 |
2005-04-28 |
Imclone Llc |
Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
|
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
RS53073B
(sr)
|
2003-11-04 |
2014-04-30 |
Novartis Vaccines And Diagnostics Inc. |
Upotreba antagonističkih anti-cd40 monoklonska antitela
|
|
EP1706425A2
(en)
|
2003-12-05 |
2006-10-04 |
John R. Schreiber |
Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse®
|
|
US20050136055A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
|
RU2377254C2
(ru)
|
2003-12-25 |
2009-12-27 |
Кирин Фарма Кабусики Кайся |
Мутанты анти-cd40 антитела
|
|
CN1956738B
(zh)
|
2004-01-09 |
2013-05-29 |
辉瑞大药厂 |
MAdCAM抗体
|
|
EP1756162A1
(en)
|
2004-03-23 |
2007-02-28 |
Biogen Idec MA Inc. |
Receptor coupling agents and therapeutic uses thereof
|
|
US20060099203A1
(en)
|
2004-11-05 |
2006-05-11 |
Pease Larry R |
B7-DC binding antibody
|
|
JP5902367B2
(ja)
*
|
2004-06-30 |
2016-04-13 |
メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ |
抗体
|
|
DK2287195T3
(da)
|
2004-07-01 |
2019-08-19 |
Innate Pharma |
Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi
|
|
US20070286855A1
(en)
*
|
2004-08-03 |
2007-12-13 |
Mayo Foundation For Medical Education And Research |
Improving treatments
|
|
US7563443B2
(en)
*
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
|
PL1836225T3
(pl)
|
2005-01-06 |
2012-05-31 |
Novo Nordisk As |
Czynniki wiążące kir i sposoby ich stosowania
|
|
US8716451B2
(en)
|
2005-01-12 |
2014-05-06 |
Kyowa Hakko Kirin Co., Ltd |
Stabilized human IgG2 and IgG3 antibodies
|
|
EA015584B1
(ru)
*
|
2005-03-23 |
2011-10-31 |
Генмаб А/С |
Антитело к cd38 человека и его применение
|
|
NZ562234A
(en)
|
2005-04-26 |
2009-09-25 |
Pfizer |
P-cadherin antibodies
|
|
WO2006125143A2
(en)
*
|
2005-05-18 |
2006-11-23 |
Novartis Ag |
Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
|
|
JP5421590B2
(ja)
*
|
2005-05-18 |
2014-02-19 |
ノバルティス アーゲー |
自己免疫および/または炎症性成分を有する疾患の診断および治療のための方法
|
|
GB0512225D0
(en)
*
|
2005-06-16 |
2005-07-27 |
Univ Sheffield |
Immunoglobulin molecules
|
|
PT3248613T
(pt)
|
2005-07-18 |
2022-03-16 |
Seagen Inc |
Conjugados de ligante de fármaco e beta-glucuronida
|
|
DK1933871T3
(da)
|
2005-09-07 |
2013-07-08 |
Amgen Fremont Inc |
Humane monoklonale antistoffer mod activin-receptor-lignende kinase-1
|
|
WO2007103048A2
(en)
*
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
CA2652599C
(en)
*
|
2006-05-03 |
2019-09-24 |
Ross Kedl |
Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
|
|
EP2258700A1
(en)
|
2006-05-09 |
2010-12-08 |
Pfizer Products Inc. |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
|
|
EP1854810A1
(en)
*
|
2006-05-09 |
2007-11-14 |
PanGenetics B.V. |
Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
|
|
CA2652148C
(en)
|
2006-05-12 |
2016-10-04 |
Fondazione Centro San Raffaele Del Monte Tabor |
Tolerogenic dendritic cells, method for their production and uses thereof
|
|
US20090074711A1
(en)
*
|
2006-09-07 |
2009-03-19 |
University Of Southhampton |
Human therapies using chimeric agonistic anti-human cd40 antibody
|
|
AU2007332473B2
(en)
*
|
2006-12-14 |
2012-09-27 |
Forerunner Pharma Research Co., Ltd. |
Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same
|
|
CA2678863A1
(en)
*
|
2007-02-23 |
2008-08-28 |
Schering Corporation |
Engineered anti-il-23p19 antibodies
|
|
MX2009009079A
(es)
*
|
2007-02-23 |
2009-08-31 |
Schering Corp |
Anticuerpos anti-il-23p19 de ingenieria.
|
|
EP3392273A1
(en)
|
2007-05-30 |
2018-10-24 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
|
EP1997830A1
(en)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV specific binding molecules and means for producing them
|
|
US8039597B2
(en)
*
|
2007-09-07 |
2011-10-18 |
Agensys, Inc. |
Antibodies and related molecules that bind to 24P4C12 proteins
|
|
BRPI0820707A2
(pt)
|
2007-11-07 |
2015-06-16 |
Genentech Inc |
Métodos e composição para avaliar a responsividade do linfoma de células b para o tratamento com anticorpos anti-cd40
|
|
SG186656A1
(en)
|
2007-12-14 |
2013-01-30 |
Bristol Myers Squibb Co |
Binding molecules to the human ox40 receptor
|
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
|
CA2731368C
(en)
|
2008-08-06 |
2013-05-14 |
Pfizer Inc. |
6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
|
|
AU2009286247A1
(en)
*
|
2008-08-29 |
2010-03-04 |
Academisch Ziekenhuis Leiden H.O.D.N. Lumc |
Delivery of a CD40 agonist to a tumor draining lymph node of a subject
|
|
EP2198878A1
(en)
|
2008-12-18 |
2010-06-23 |
University Of Miami |
Polypeptide bombesin antagonists
|
|
JO3382B1
(ar)
*
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
|
AU2016244220B2
(en)
*
|
2008-12-23 |
2018-05-17 |
Amgen Inc. |
Human CGRP receptor binding proteins
|
|
AU2010229192A1
(en)
*
|
2009-03-06 |
2011-09-29 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 24P4C12 proteins
|
|
EP2406286B1
(en)
|
2009-03-10 |
2016-05-18 |
Baylor Research Institute |
Anti-cd40 antibodies and uses thereof
|
|
CN105837691B
(zh)
*
|
2009-03-10 |
2021-06-29 |
贝勒研究院 |
靶向抗原呈递细胞的癌症疫苗
|
|
JP2012520073A
(ja)
|
2009-03-10 |
2012-09-06 |
ベイラー リサーチ インスティテュート |
抗原提示細胞ターゲティングワクチン
|
|
US9617600B2
(en)
|
2009-04-18 |
2017-04-11 |
Genentech, Inc. |
Methods for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies
|
|
JP5694921B2
(ja)
*
|
2009-04-20 |
2015-04-01 |
協和発酵キリン株式会社 |
アミノ酸変異が導入されたIgG2を有する抗体
|
|
TW201138843A
(en)
|
2009-12-18 |
2011-11-16 |
Colgate Palmolive Co |
Biguanide preservation of precipitated calcium carbonate
|
|
WO2011083391A2
(en)
|
2010-01-05 |
2011-07-14 |
Pfizer Inc. |
Biomarkers for anti-igf-ir cancer therapy
|
|
RS60612B1
(sr)
|
2010-03-31 |
2020-08-31 |
Boehringer Ingelheim Int |
Anti-cd40 antitela
|
|
GB201006096D0
(en)
*
|
2010-04-13 |
2010-05-26 |
Alligator Bioscience Ab |
Novel compositions and uses thereof
|
|
FR2959994B1
(fr)
|
2010-05-12 |
2012-08-24 |
Lfb Biotechnologies |
Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii
|
|
MX337040B
(es)
|
2010-09-09 |
2016-02-09 |
Pfizer |
Moleculas de union a 4-1bb.
|
|
WO2012041635A1
(en)
*
|
2010-09-29 |
2012-04-05 |
Universite De Liege |
Combination of an agonistic anti-cd40 monoclonal antibody or a cd40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis
|
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
|
EP2640750A1
(en)
*
|
2010-11-16 |
2013-09-25 |
Boehringer Ingelheim International GmbH |
Agents and methods for treating diseases that correlate with bcma expression
|
|
PL2663580T3
(pl)
*
|
2011-01-10 |
2017-08-31 |
Ct Atlantic Ltd. |
Terapia skojarzona obejmująca przeciwciała wiążące antygen związany z nowotworem
|
|
GB201103578D0
(en)
|
2011-03-02 |
2011-04-13 |
Sabrepharm Ltd |
Dipyridinium derivatives
|
|
HUE065915T2
(hu)
|
2011-03-11 |
2024-06-28 |
Beth Israel Deaconess Medical Ct Inc |
Anti-CD40 antitestek és alkalmazásaik
|
|
CA3019531A1
(en)
|
2011-04-19 |
2012-10-26 |
Pfizer Inc. |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
|
US9475879B2
(en)
|
2011-04-21 |
2016-10-25 |
Bristol-Myers Squibb Company |
Antibody polypeptides that antagonize CD40
|
|
KR20140059168A
(ko)
*
|
2011-04-21 |
2014-05-15 |
더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 |
시신경 척수염 치료용 조성물 및 치료 방법
|
|
CN103635488B
(zh)
|
2011-04-29 |
2016-12-14 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
|
EP2710042A2
(en)
|
2011-05-16 |
2014-03-26 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
GB201115280D0
(en)
*
|
2011-09-05 |
2011-10-19 |
Alligator Bioscience Ab |
Antibodies, uses and methods
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
ES2806146T3
(es)
*
|
2011-09-22 |
2021-02-16 |
Amgen Inc |
Proteínas de unión al antígeno CD27L
|
|
CN104203982B
(zh)
|
2011-10-28 |
2018-08-31 |
特瓦制药澳大利亚私人有限公司 |
多肽构建体及其用途
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
|
WO2013091661A2
(en)
*
|
2011-12-23 |
2013-06-27 |
Aarhus Universitet |
Proteolytic resistant protein affinity tag
|
|
ES2886123T3
(es)
|
2012-01-31 |
2021-12-16 |
Regeneron Pharma |
Anticuerpos anti-asic1 y usos de los mismos
|
|
AR090263A1
(es)
*
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
JP5798199B2
(ja)
*
|
2012-03-08 |
2015-10-21 |
国立研究開発法人科学技術振興機構 |
抗がん剤
|
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
|
NZ701324A
(en)
|
2012-05-04 |
2016-09-30 |
Pfizer |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
|
EP3882337A1
(en)
|
2012-06-18 |
2021-09-22 |
Ospedale San Raffaele S.r.l. |
Compositions and methods for diminishing an immune response
|
|
EP2914627B1
(en)
|
2012-10-30 |
2021-04-07 |
Apexigen, Inc. |
Anti-cd40 antibodies and methods of use
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
JP6539585B2
(ja)
|
2013-02-01 |
2019-07-03 |
デンドロサイト バイオテック ピーティーワイ リミテッド |
抗cd83抗体及びその使用
|
|
WO2014144817A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Inhibitory polypeptides specific to wnt inhibitors
|
|
KR20160006168A
(ko)
|
2013-03-18 |
2016-01-18 |
바이오서오엑스 프로덕스 비.브이. |
인간화 항-cd134(ox40) 항체 및 이의 용도
|
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
|
ES2774976T3
(es)
|
2013-04-29 |
2020-07-23 |
Teva Pharmaceuticals Australia Pty Ltd |
Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
|
|
EP3007711B1
(en)
|
2013-06-14 |
2020-10-21 |
Psioxus Therapeutics Limited |
A dosing regime and formulations for type b adenoviruses
|
|
EP3011353B1
(en)
|
2013-06-17 |
2017-02-15 |
Koninklijke Philips N.V. |
Magnetic resonance imaging subject support
|
|
GB201311487D0
(en)
*
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Bispecific molecules
|
|
US11273204B2
(en)
|
2013-08-08 |
2022-03-15 |
Cytune Pharma |
IL-15 and IL-15RAPLHA sushi domain based immunocytokines
|
|
WO2015035215A1
(en)
|
2013-09-05 |
2015-03-12 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
|
TR201802728T4
(tr)
|
2013-10-25 |
2018-03-21 |
Psioxus Therapeutics Ltd |
Heterolog genlerle donatılmış onkolitik adenovirüsler.
|
|
GB201322583D0
(en)
*
|
2013-12-19 |
2014-02-05 |
Alligator Bioscience Ab |
Antibodies
|
|
KR20160085888A
(ko)
*
|
2013-12-20 |
2016-07-18 |
에프. 호프만-라 로슈 아게 |
항-ang2 항체 및 cd40 작용제를 사용한 조합 요법
|
|
AU2015204503B2
(en)
|
2014-01-13 |
2020-07-09 |
Baylor Research Institute |
Novel vaccines against HPV and HPV-related diseases
|
|
US10435475B2
(en)
|
2014-03-07 |
2019-10-08 |
Bristol-Myers Squibb Company |
Method of using antibody polypeptides that antagonize CD40 to treat IBD
|
|
RU2016142476A
(ru)
|
2014-03-31 |
2018-05-07 |
Дженентек, Инк. |
Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
|
|
KR102526945B1
(ko)
*
|
2014-04-30 |
2023-04-27 |
막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 |
Cd269에 대한 인간화 항체
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
EP3143404B1
(en)
|
2014-05-16 |
2018-08-29 |
Amgen Inc. |
Assay for detecting th1 and th2 cell populations
|
|
GB201413665D0
(en)
|
2014-07-03 |
2014-09-17 |
Transimmune Ag And Yale University |
Method for obtaining globally activated monocytes
|
|
EP3552665A3
(en)
|
2014-08-12 |
2019-12-18 |
Alligator Bioscience AB |
Antibodies
|
|
EP3070102A1
(en)
|
2015-03-18 |
2016-09-21 |
F. Hoffmann-La Roche AG |
Combination therapy of antibodies human cd40 activating antibodies and anti human pld-1 antibodies
|
|
SG11201701039PA
(en)
*
|
2014-08-14 |
2017-03-30 |
Hoffmann La Roche |
Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1
|
|
WO2016044224A1
(en)
|
2014-09-15 |
2016-03-24 |
Amgen Inc. |
Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
|
|
US10870704B2
(en)
|
2014-10-23 |
2020-12-22 |
Kira Biotech Pty Limited |
CD83 binding proteins and uses thereof
|
|
US9107906B1
(en)
|
2014-10-28 |
2015-08-18 |
Adma Biologics, Inc. |
Compositions and methods for the treatment of immunodeficiency
|
|
AU2015339128C1
(en)
*
|
2014-10-29 |
2021-12-16 |
Seagen Inc. |
Dosage and administration of non-fucosylated anti-CD40 antibodies
|
|
EA037749B1
(ru)
|
2014-10-29 |
2021-05-18 |
Тева Фармасьютикалз Острэйлиа Пти Лтд |
ВАРИАНТЫ ИНТЕРФЕРОНА 2b
|
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
|
LT3283527T
(lt)
|
2015-04-13 |
2021-03-25 |
Five Prime Therapeutics, Inc. |
Kompleksinė terapija vėžio gydymui
|
|
JOP20200116A1
(ar)
|
2015-04-24 |
2017-06-16 |
Amgen Inc |
طرق لعلاج أو الوقاية من الصداع النصفي
|
|
BR122018004815A2
(pt)
|
2015-04-30 |
2019-09-10 |
Psioxus Therapeutics Ltd |
adenovírus oncolítico que codifica proteína b7
|
|
IL302486A
(en)
|
2015-06-24 |
2023-06-01 |
Hoffmann La Roche |
Antibodies against the transnephrine receptor with adapted affinity
|
|
MX395257B
(es)
*
|
2015-06-29 |
2025-03-25 |
Bristol Myers Squibb Co |
Anticuerpos para cd40.
|
|
MX2017016502A
(es)
*
|
2015-06-29 |
2018-03-12 |
Univ Rockefeller |
Anticuerpos contra cd40 con actividad agonista mejorada.
|
|
CA2986705A1
(en)
|
2015-07-16 |
2017-01-19 |
Biokine Therapeutics Ltd. |
A cxcr4 inhibitor and a pdi antagonist for use in treating cancer
|
|
EP3307322B1
(en)
|
2015-09-04 |
2021-02-17 |
Primatope Therapeutics Inc. |
Humanized anti-cd40 antibodies and uses thereof
|
|
MX2018003905A
(es)
|
2015-09-30 |
2018-09-06 |
Janssen Biotech Inc |
Anticuerpos agonistas que se unen específicamente a cd40 humana y métodos de uso.
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
JP6657392B2
(ja)
|
2015-10-02 |
2020-03-04 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗ヒトcd20/ヒトトランスフェリン受容体抗体及び使用方法
|
|
GB2543550A
(en)
|
2015-10-21 |
2017-04-26 |
Hox Therapeutics Ltd |
Peptides
|
|
SI3370768T1
(sl)
|
2015-11-03 |
2022-04-29 |
Janssen Biotech, Inc. |
Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe
|
|
CN114835797A
(zh)
*
|
2015-11-16 |
2022-08-02 |
Ubi蛋白公司 |
用于延长蛋白质半衰期的方法
|
|
DE212016000029U1
(de)
*
|
2015-12-07 |
2017-07-30 |
Opi Vi - Ip Holdco Llc |
Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
|
|
EA201891022A1
(ru)
|
2015-12-17 |
2019-01-31 |
Псайоксус Терапьютикс Лимитед |
Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
|
|
CA3016534A1
(en)
|
2016-03-04 |
2017-09-08 |
The Rockefeller University |
Antibodies to cd40 with enhanced agonist activity
|
|
WO2017156349A1
(en)
|
2016-03-10 |
2017-09-14 |
Cold Genesys, Inc. |
Methods of treating solid or lymphatic tumors by combination therapy
|
|
JP7034489B2
(ja)
|
2016-03-15 |
2022-03-14 |
アイタブメッド (エイチケイ) リミテッド |
多重特異性Fab融合タンパクおよびその使用
|
|
US10894823B2
(en)
|
2016-03-24 |
2021-01-19 |
Gensun Biopharma Inc. |
Trispecific inhibitors for cancer treatment
|
|
BR112018069273A2
(pt)
|
2016-03-25 |
2019-01-22 |
Seattle Genetics Inc |
métodos para preparação de um composto e para tratamento de um indivíduo com uma malignidade hematológica, composto, composição, e, intermediário ligante de fármaco ou composto ligante de fármaco
|
|
SG10201914132RA
(en)
|
2016-05-27 |
2020-03-30 |
Abbvie Biotherapeutics Inc |
Anti-cd40 antibodies and their uses
|
|
CA3025345A1
(en)
|
2016-05-27 |
2017-11-30 |
Abbvie Biotherapeutics Inc. |
Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
|
|
DK3468997T5
(da)
|
2016-06-08 |
2024-09-09 |
Xencor Inc |
Behandling af IgG4-relaterede sygdomme med anti-CD9-antistoffer med tværbinding til CD32B
|
|
WO2017211321A1
(zh)
*
|
2016-06-08 |
2017-12-14 |
上海交通大学医学院 |
增强激动型抗体活性的抗体重链恒定区序列
|
|
BR112018076260A2
(pt)
|
2016-06-20 |
2019-03-26 |
Kymab Limited |
anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
|
|
UA128304C2
(uk)
|
2016-07-14 |
2024-06-05 |
Ґенмаб А/С |
Мультиспецифічне антитіло до cd40 і cd137
|
|
EP3487522A4
(en)
|
2016-07-19 |
2020-04-01 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-cd47 combination therapy
|
|
SG11201900744SA
(en)
|
2016-08-12 |
2019-02-27 |
Janssen Biotech Inc |
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
|
|
CN109863170B
(zh)
|
2016-08-12 |
2024-08-16 |
詹森生物科技公司 |
具有增强的激动作用和效应子功能的工程化抗体及其他含Fc结构域分子
|
|
WO2018036852A1
(en)
|
2016-08-25 |
2018-03-01 |
F. Hoffmann-La Roche Ag |
Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
|
|
GB201713765D0
(en)
|
2017-08-28 |
2017-10-11 |
Psioxus Therapeutics Ltd |
Modified adenovirus
|
|
CN119614520A
(zh)
|
2016-08-29 |
2025-03-14 |
阿卡米斯生物公司 |
携带双特异性t细胞衔接器的腺病毒
|
|
KR102019033B1
(ko)
|
2016-11-11 |
2019-09-06 |
다이노나(주) |
Cd40에 특이적으로 결합하는 항체 및 그의 용도
|
|
WO2018115003A2
(en)
|
2016-12-19 |
2018-06-28 |
Glenmark Pharmaceuticals S.A. |
Novel tnfr agonists and uses thereof
|
|
JP7304287B2
(ja)
|
2016-12-22 |
2023-07-06 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗pd-l1/pd1治療の不成功後の、抗pd-l1抗体との組み合わせでの抗csf-1r抗体を用いた腫瘍の治療
|
|
CN109071656B
(zh)
|
2017-01-05 |
2021-05-18 |
璟尚生物制药公司 |
检查点调节物拮抗剂
|
|
CA3049842A1
(en)
*
|
2017-02-02 |
2018-08-09 |
Silverback Therapeutics, Inc. |
Construct-peptide compositions and methods of use thereof
|
|
KR20250140128A
(ko)
|
2017-02-10 |
2025-09-24 |
젠맵 비. 브이 |
폴리펩티드 변이체 및 그의 용도
|
|
CN110418846A
(zh)
|
2017-03-14 |
2019-11-05 |
美国安进公司 |
细胞培养物中产生的抗体的总去岩藻糖基化糖型的控制
|
|
US10259865B2
(en)
|
2017-03-15 |
2019-04-16 |
Adma Biologics, Inc. |
Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
|
|
US11730822B2
(en)
|
2017-03-24 |
2023-08-22 |
Seagen Inc. |
Process for the preparation of glucuronide drug-linkers and intermediates thereof
|
|
AU2018241780A1
(en)
*
|
2017-03-29 |
2019-08-15 |
Glycotope Gmbh |
Humanized anti-CD40 antibodies
|
|
US11319408B2
(en)
|
2017-03-30 |
2022-05-03 |
Nof Corporation |
Hydrophilic polymer derivative having self-immolative acetal linker and conjugate using same
|
|
US11419946B2
(en)
|
2017-03-30 |
2022-08-23 |
Nof Corporation |
Heterobifunctional monodispersed polyethylene glycol and conjugate using same
|
|
CA3053358A1
(en)
|
2017-04-04 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
|
|
BR112019021411A2
(pt)
|
2017-04-13 |
2020-05-05 |
Hoffmann La Roche |
métodos para tratar ou retardar a progressão do câncer e para melhorar a função, usos de um imunoconjugado, de um agonista, de um antagonista, composições, kit e invenção
|
|
CN110267989B
(zh)
*
|
2017-06-01 |
2023-04-04 |
江苏恒瑞医药股份有限公司 |
抗cd40抗体、其抗原结合片段及其医药用途
|
|
WO2018220207A1
(en)
*
|
2017-06-01 |
2018-12-06 |
Psioxus Therapeutics Limited |
Oncolytic virus and method
|
|
JP2020521788A
(ja)
*
|
2017-06-02 |
2020-07-27 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
免疫アゴニストの投与経路
|
|
EP3418302A1
(en)
|
2017-06-19 |
2018-12-26 |
F. Hoffmann-La Roche AG |
Administration routes for immune agonists
|
|
SG11202000298VA
(en)
|
2017-07-14 |
2020-02-27 |
Pfizer |
Antibodies to madcam
|
|
WO2019036855A1
(en)
|
2017-08-21 |
2019-02-28 |
Adagene Inc. |
Anti-cd137 molecules and use thereof
|
|
IL272770B2
(en)
*
|
2017-09-19 |
2025-08-01 |
Mab Discovery Gmbh |
Agonistic cd40 antibodies
|
|
US10610585B2
(en)
|
2017-09-26 |
2020-04-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating and preventing HIV
|
|
AU2018363922B2
(en)
|
2017-11-08 |
2025-06-12 |
Kyowa Kirin Co., Ltd. |
Bispecific antibody which binds to CD40 and EpCAM
|
|
KR102813744B1
(ko)
|
2017-12-27 |
2025-05-28 |
브리스톨-마이어스 스큅 컴퍼니 |
항-cd40 항체 및 그의 용도
|
|
CN109971723B
(zh)
*
|
2017-12-28 |
2023-07-07 |
上海细胞治疗研究院 |
包含CD40抗体与muc1特异性嵌合抗原受体基因的T细胞及其用途
|
|
CN109971717B
(zh)
*
|
2017-12-28 |
2023-06-20 |
上海细胞治疗研究院 |
共表达cd40抗体与间皮素特异性嵌合抗原受体的t细胞及其用途
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
GB201801614D0
(en)
|
2018-01-31 |
2018-03-14 |
Psioxus Therapeutics Ltd |
Formulation
|
|
WO2019148444A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Anti-ctla4 antibodies and methods of making and using the same
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
EP3766917B1
(en)
|
2018-03-13 |
2023-04-19 |
NOF Corporation |
Heterobifunctional compound having monodispersed polyethylene glycol in main chain or side chain
|
|
SG11202009216YA
(en)
|
2018-03-26 |
2020-10-29 |
Amgen Inc |
Total afucosylated glycoforms of antibodies produced in cell culture
|
|
BR112020019882A2
(pt)
|
2018-04-02 |
2021-01-05 |
Amgen Inc. |
Composições de erenumabe e seus usos
|
|
AU2019255781A1
(en)
*
|
2018-04-20 |
2020-10-29 |
Lyvgen Biopharma Holdings Limited |
Anti-CD40 antibodies and uses thereof
|
|
TW202003576A
(zh)
*
|
2018-05-10 |
2020-01-16 |
美商艾博視訊有限公司 |
活化cd40之單株抗體及其用途
|
|
WO2019232533A1
(en)
*
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Combination treatments of hsp90 inhibitors for enhancing tumor immunogenicity and methods of use thereof
|
|
KR20210035805A
(ko)
|
2018-06-15 |
2021-04-01 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
|
|
WO2020006516A1
(en)
|
2018-06-29 |
2020-01-02 |
Gensun Biopharma, Inc. |
Antitumor immune checkpoint regulator antagonists
|
|
KR102715542B1
(ko)
|
2018-08-20 |
2024-10-08 |
화이자 인코포레이티드 |
항-gdf15 항체, 조성물 및 사용 방법
|
|
EP3847196A4
(en)
|
2018-09-07 |
2023-01-04 |
ITabMed (HK) Limited |
BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
|
|
EP3860653A1
(en)
|
2018-10-05 |
2021-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and systems for controlling the agonistic properties of antibody variable domains by light
|
|
JP2022509156A
(ja)
|
2018-11-30 |
2022-01-20 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
抗cd40抗体、その抗原結合フラグメント、およびその医学的使用
|
|
CN112839961B
(zh)
|
2018-11-30 |
2023-04-04 |
江苏恒瑞医药股份有限公司 |
一种cd40抗体药物组合物及其用途
|
|
US20220089758A1
(en)
*
|
2019-01-22 |
2022-03-24 |
Revmab Biosciences Usa, Inc. |
Novel anti-cd40 antibodies
|
|
US10570210B1
(en)
|
2019-03-04 |
2020-02-25 |
Beijing Mabworks Biotech Co.Ltd |
Antibodies binding CD40 and uses thereof
|
|
WO2020193718A1
(en)
|
2019-03-27 |
2020-10-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Recombinant proteins with cd40 activating properties
|
|
CA3136491A1
(en)
*
|
2019-04-10 |
2020-10-15 |
Nankai University |
Anti-cd40 antibodies and uses thereof
|
|
MA55805A
(fr)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V Inc |
Métodes de modulation de l'activité immunitaire
|
|
CA3140385A1
(en)
|
2019-05-15 |
2020-11-19 |
Kyowa Kirin Co., Ltd. |
Bispecific antibody binding to cd40 and fap
|
|
TWI875760B
(zh)
|
2019-05-15 |
2025-03-11 |
日商協和麒麟股份有限公司 |
與cd40及gpc3結合之雙專一性抗體
|
|
WO2020263312A1
(en)
|
2019-06-28 |
2020-12-30 |
Gensun Biopharma, Inc. |
ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
|
|
US20220370418A1
(en)
|
2019-09-09 |
2022-11-24 |
Basilea Pharmaceutica International AG |
Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
|
|
CN114450324B
(zh)
|
2019-09-26 |
2024-02-27 |
日油株式会社 |
具有肽连接子的异双官能单分散聚乙二醇
|
|
KR20220069982A
(ko)
|
2019-09-26 |
2022-05-27 |
암젠 인크 |
항체 조성물의 생산 방법
|
|
AU2020398327A1
(en)
*
|
2019-12-03 |
2022-07-14 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins and uses thereof
|
|
US20230114107A1
(en)
|
2019-12-17 |
2023-04-13 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
|
US11926672B2
(en)
|
2019-12-20 |
2024-03-12 |
Amgen Inc. |
Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors
|
|
US20210214454A1
(en)
*
|
2020-01-10 |
2021-07-15 |
Symphogen A/S |
Anti-cd40 antibodies and compositions
|
|
IL272194A
(en)
|
2020-01-22 |
2021-07-29 |
Yeda Res & Dev |
Multi-target antibodies for use in the treatment of diseases
|
|
CN115702002A
(zh)
|
2020-04-23 |
2023-02-14 |
朝途生物疗法株式会社 |
改良肽疫苗
|
|
WO2021228178A1
(en)
|
2020-05-13 |
2021-11-18 |
Adagene Ag |
Compositions and methods for treating cancer
|
|
JP2023528207A
(ja)
|
2020-05-14 |
2023-07-04 |
モレキュラー パートナーズ アクチェンゲゼルシャフト |
組換えcd40結合タンパク質及びそれらの使用
|
|
BR112022023049A2
(pt)
|
2020-05-14 |
2022-12-20 |
Molecular Partners Ag |
Proteínas multiespecíficas
|
|
JP2023528017A
(ja)
|
2020-05-26 |
2023-07-03 |
アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) |
重症急性呼吸器症候群コロナウイルス2(sars-cov-2)ポリペプチドおよびワクチン目的でのその使用
|
|
GB202008003D0
(en)
|
2020-05-28 |
2020-07-15 |
Quine Medical Ab |
Anti-CD40 antibody
|
|
WO2021247892A1
(en)
|
2020-06-04 |
2021-12-09 |
Amgen Inc. |
Assessment of cleaning procedures of a biotherapeutic manufacturing process
|
|
US20230355804A1
(en)
|
2020-06-29 |
2023-11-09 |
Flagship Pioneering Innovations V, Inc. |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
|
JP2023538105A
(ja)
*
|
2020-08-21 |
2023-09-06 |
ウーシー・バイオロジクス・(シャンハイ)・カンパニー・リミテッド |
Cd40アゴニスト抗体及び使用方法
|
|
AU2021360897A1
(en)
|
2020-10-15 |
2023-05-25 |
Amgen Inc. |
Relative unpaired glycans in antibody production methods
|
|
KR20230107260A
(ko)
|
2020-11-12 |
2023-07-14 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
Sars-cov-2 스파이크 단백질의 수용체-결합 도메인에 접합되거나 융합된 항체, 및 백신 목적을 위한 이의 용도
|
|
CA3205280A1
(en)
|
2020-12-23 |
2022-06-30 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells
|
|
WO2022147481A1
(en)
|
2020-12-30 |
2022-07-07 |
Ansun Biopharma Inc. |
Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
|
|
EP4274854A4
(en)
*
|
2021-01-08 |
2025-03-26 |
Bristol-Myers Squibb Company |
Antibodies and antigen binding peptides for factor xia inhibitors and uses thereof
|
|
WO2022152701A1
(en)
|
2021-01-13 |
2022-07-21 |
F. Hoffmann-La Roche Ag |
Combination therapy
|
|
MX2023008986A
(es)
|
2021-01-29 |
2023-08-15 |
Inst Nat Sante Rech Med |
Polipeptidos antigenicos de chlamydia trachomatis y usos de los mismos con fines de vacuna.
|
|
WO2022165260A1
(en)
|
2021-01-29 |
2022-08-04 |
Iovance Biotherapeutics, Inc. |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
|
TWI843989B
(zh)
|
2021-02-19 |
2024-06-01 |
美商美威高能離子醫療系統公司 |
用於粒子治療系統之支架
|
|
JP2024509915A
(ja)
|
2021-03-09 |
2024-03-05 |
ジェンマブ エー/エス |
治療におけるcd40およびcd137に対する多重特異性結合物質
|
|
CA3214085A1
(en)
|
2021-03-31 |
2022-10-06 |
Darby Rye Schmidt |
Thanotransmission polypeptides and their use in treating cancer
|
|
TW202317614A
(zh)
|
2021-06-07 |
2023-05-01 |
美商安進公司 |
使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平
|
|
CA3223842A1
(en)
*
|
2021-06-28 |
2023-01-05 |
Yuan Lin |
Anti-cd40 antibody, antigen-binding fragment and medical use thereof
|
|
KR20240026507A
(ko)
|
2021-06-29 |
2024-02-28 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
|
|
CA3225254A1
(en)
|
2021-07-13 |
2023-01-19 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
|
CN118234749A
(zh)
*
|
2021-09-17 |
2024-06-21 |
诺华股份有限公司 |
用于预防异种移植中的移植物排斥的方法
|
|
US20240392026A1
(en)
*
|
2021-10-01 |
2024-11-28 |
Mab Discovery Gmbh |
Agonistic cd40 antibodies as immune stimulatory agents
|
|
JP2024537100A
(ja)
|
2021-10-05 |
2024-10-10 |
アムジエン・インコーポレーテツド |
Fcガンマ受容体II結合、及びグリカン含量
|
|
US12234294B2
(en)
|
2021-11-05 |
2025-02-25 |
Kiniksa Pharmaceuticals, Gmbh |
Pharmaceutical composition of a humanized anti-CD40 antibody
|
|
KR20240103030A
(ko)
|
2021-11-17 |
2024-07-03 |
인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 |
범용 사르베코바이러스 백신
|
|
US20250099588A1
(en)
|
2022-01-28 |
2025-03-27 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
IL315487A
(en)
*
|
2022-03-07 |
2024-11-01 |
Agenus Inc |
ANTI-ILT2 antibodies and their uses
|
|
WO2023193239A1
(en)
|
2022-04-08 |
2023-10-12 |
Peter Peizhi Luo |
Anti-cd28 antibodies and methods of use thereof
|
|
EP4507779A1
(en)
|
2022-04-14 |
2025-02-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for controlling the tumor cell killing by light
|
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
KR20250019077A
(ko)
|
2022-05-31 |
2025-02-07 |
퓨쳐진 바이오파머쓰티컬 (베이징) 코., 엘티디. |
항-cd40 항체 및 항-pd-l1×cd40 이중특이성 항체 및 이의 용도
|
|
WO2024054992A1
(en)
|
2022-09-09 |
2024-03-14 |
Bristol-Myers Squibb Company |
Methods of separating chelator
|
|
JP2025530110A
(ja)
*
|
2022-09-20 |
2025-09-11 |
カーラス・バイオロジクス・ピーティーワイ・リミテッド |
二重特異性ポリペプチド及びその使用
|
|
EP4598576A1
(en)
*
|
2022-10-04 |
2025-08-13 |
Memorial Sloan-Kettering Cancer Center |
Anti-cd40 antibodies and uses thereof
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
WO2024074571A1
(en)
|
2022-10-05 |
2024-04-11 |
Institut National de la Santé et de la Recherche Médicale |
Dc-targeting vaccine against nipah virus infection
|
|
WO2024118836A1
(en)
|
2022-11-30 |
2024-06-06 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes with shortened rep step
|
|
WO2024115725A1
(en)
|
2022-12-01 |
2024-06-06 |
BioNTech SE |
Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
|
|
CN115969997B
(zh)
*
|
2022-12-19 |
2024-02-13 |
华润生物医药有限公司 |
一种靶向cldn18.2的抗体药物偶联物及其应用
|
|
CN116375870B
(zh)
*
|
2022-12-30 |
2023-09-15 |
优睿赛思(武汉)生物科技有限公司 |
抗人cd40蛋白的人源化抗体、制备方法及其应用
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2024213635A1
(en)
*
|
2023-04-12 |
2024-10-17 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins for use for the treatment or prevention of hepatitis delta virus infection
|
|
WO2024220916A1
(en)
|
2023-04-20 |
2024-10-24 |
Amgen Inc. |
Methods of determining relative unpaired glycan content
|
|
WO2025038600A1
(en)
|
2023-08-14 |
2025-02-20 |
Amgen Inc. |
Methods for reducing yellow color
|
|
WO2025043103A2
(en)
*
|
2023-08-24 |
2025-02-27 |
The Trustees Of Columbia University In The City Of New York |
Human protective neutralizing and non-neutralizing antibodies and their use against influenza viruses
|
|
WO2025101820A1
(en)
|
2023-11-08 |
2025-05-15 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
CN120424223A
(zh)
*
|
2024-02-04 |
2025-08-05 |
苏州泽璟生物制药股份有限公司 |
包含lrrc15抗原结合结构域的多特异性抗体
|
|
WO2025245964A1
(zh)
*
|
2024-05-28 |
2025-12-04 |
中生康元生物科技(北京)有限公司 |
一种树突状细胞制剂及其制备方法
|